众生药业(002317.SZ)：控股子公司获得一类创新药昂拉地韦颗粒III期临床试验伦理批件

Core Viewpoint - Zhongsheng Pharmaceutical (002317.SZ) announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., received approval from the Medical Ethics Committee of Beijing Children's Hospital for a clinical research project to conduct a Phase III clinical trial of the innovative drug Anladiwei granules for the treatment of uncomplicated influenza A in children aged 2 to 11 years [1] Group 1 - The clinical trial is a multicenter, randomized, double-blind, positive-controlled study [1] - Anladiwei tablets (brand name: Anruiwei) are the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus [1] - The drug is designed for the treatment of uncomplicated influenza A in adults and is characterized by rapid action, strong efficacy, and low resistance [1] Group 2 - Anladiwei was approved for market launch by the National Medical Products Administration in May 2025 [1]